This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M35.0 (Sjögren syndrome) | Special Copayment Reduction: V139 (rare disease) |
| B. Synonyms | Sicca syndrome [Sjögren] | Sjögren syndrome with keratoconjunctivitis (H19.3*) | Sjögren syndrome with myopathy (G73.7*) | Sjögren syndrome with lung involvement (J99.1*) | Sjögren syndrome with renal tubulo-interstitial disorders (N16.4*) |
| C. Adult onset | Very high likelihood of first presenting in adulthood — more than 80% of Sjögren syndrome cases are first diagnosed in middle-aged and older adults (mainly in their 40s–60s). It is overwhelmingly more common in women, and childhood onset is very rare. Symptoms such as dry eye and dry mouth develop gradually, and diagnosis is commonly delayed for years. |
| 1. History | 1888: Mikulicz describes a case of dry eyes and mouth → 1933: Henrik Sjögren's doctoral thesis describes the triad of keratoconjunctivitis sicca + xerostomia + arthritis → 1965: clinical criteria by Bloch et al. → 2002: AECG classification criteria → 2016: ACR/EULAR classification criteria established. |
| 2. Causes | Multifactorial etiology: genetic predisposition (HLA-DR3/DQ2, IRF5, STAT4), environmental triggers (Epstein-Barr virus, coronavirus), hormonal factors (estrogen decline). Autoimmune response targeting the exocrine glands (lacrimal and salivary glands). |
| 3. Genetics | Strongest association with HLA-DR3 (DRB1*03:01)-DQ2. HLA association with anti-Ro/SSA and anti-La/SSB. GWAS: variants in IRF5, STAT4, BLK, TNIP1, CXCR5. Concordance in identical twins about 14–24%. Polygenic complex inheritance. |
| 4. General epidemiology | Prevalence about 0.1–0.6% (1 in 1,000–6,000 people). Female:male about 9–15:1. Frequent in the 40s–60s. Prevalence in Korea about 0.06–0.1%. Risk of B-cell lymphoma about 15–20 times higher than in the general population. |
| 5. Pathophysiology | Activation of exocrine gland epithelial cells → TLR signaling → type I interferon → infiltration of CD4+ T cells and B cells → anti-Ro/SSA and anti-La/SSB autoantibodies → apoptosis and functional decline of gland cells → dryness symptoms. B-cell hyperactivation → lymphoma risk. |
| 6. Symptoms | Dryness symptoms: dry eye (sandpaper sensation, redness, photosensitivity), dry mouth (dysphagia, dental caries, taste changes). Systemic: extreme fatigue, arthralgia and myalgia. Extraglandular involvement: renal tubular acidosis, ILD, peripheral neuropathy, vasculitis. |
| 7. Signs | Parotid enlargement (painless, symmetric or asymmetric), positive Schirmer test (≤5 mm/5 min), fluorescein corneal staining (corneal epithelial defects), decreased salivary flow, lymphocytic infiltration on lip biopsy (focus score ≥1), positive anti-Ro/SSA antibody. |
| 8. Screening | Anti-Ro/SSA, anti-La/SSB antibodies, and ANA in patients complaining of dry eye and dry mouth. Schirmer test and oral examination in all patients with dryness symptoms. Lymphoma surveillance: parotid ultrasound, serum immunoglobulins. |
| 9. Diagnosis | 2016 ACR/EULAR classification criteria (total of 4 points or more): positive lip biopsy 3 points, positive anti-Ro/SSA 3 points, abnormal ocular staining score 1 point, positive Schirmer 1 point, decreased salivary flow 1 point. Total of 4 points or more confirms the diagnosis. |
| 10. Treatment | Dryness symptoms: artificial tears (hyaluronic acid, carboxymethylcellulose), pilocarpine and cevimeline (M3 muscarinic receptor agonists). Systemic therapy: hydroxychloroquine, methotrexate. Extraglandular involvement: steroids + MMF/AZA. Lymphoma: standard chemotherapy. |
| 11. Prognosis | Life expectancy is generally close to normal, but quality of life is greatly reduced. Extraglandular involvement (neurological, pulmonary, renal), B-cell lymphoma (poor prognosis when it occurs), and cryoglobulinemia are poor prognostic factors. Intensify lymphoma surveillance when anti-Ro is positive and the parotid is enlarged. |
| 12. Prevention | Primary: no established prevention; viral vaccination, smoking cessation. Secondary: early recognition of dryness symptoms, autoantibody screening. Tertiary: regular ophthalmologic and dental care, education on caries prevention, regular evaluation for extraglandular involvement, early detection of lymphoma. |
| 13. References | Shiboski CH, et al. 2016 ACR/EULAR classification criteria for pSS. Arthritis Rheumatol. 2017 … and 9 other papers |
The history of Sjögren syndrome begins with clinical observations of groups of patients complaining of dryness symptoms in European medicine in the late 19th century. In 1888, the Polish-German physician Johann Mikulicz-Radecki described a case of a patient with bilateral enlargement of the parotid glands and lacrimal glands, with dry mouth and dry eyes. This case later became known as 'Mikulicz disease', and the term was used interchangeably with Sjögren syndrome before later being distinguished. Between the late 19th and early 20th centuries, other physicians also reported patients with dryness symptoms and salivary gland lesions, but there was no conceptual framework to unify them into a single independent disease.
In the early 20th century, the Swedish ophthalmologist Henrik Sjögren (1899–1986) made a decisive contribution to establishing this disease as an independent clinical entity. In 1933, at the Karolinska Institute in Stockholm, Sjögren published his doctoral thesis 'A contribution to the knowledge of keratoconjunctivitis sicca (Zur Kenntnis der keratoconjunctivitis sicca)', in which he first systematically argued that the triad of dry eye (keratoconjunctivitis sicca), dry mouth (xerostomia), and chronic arthritis (then called 'polyarthrorheumatism') constitutes a single systemic autoimmune disease. Sjögren analyzed 19 patients in detail, emphasized that the disease is a systemic disease rather than a mere ophthalmologic problem, and developed the 'Sjögren corneal staining method' to assess corneal epithelial damage. His research was initially received skeptically in Scandinavian medicine of the time, but gained international recognition in the 1940s–50s, and the syndrome came to bear his name.
In the 1950s–60s, the association of Sjögren syndrome with other autoimmune diseases (lupus, rheumatoid arthritis, systemic sclerosis) was gradually recognized, and the concepts of 'secondary Sjögren syndrome' and 'primary Sjögren syndrome' were established. In 1965, Bloch et al. first proposed clinical classification criteria, laying the foundation for standardization of research. In the 1970s–80s, the discovery of anti-Ro/SSA and anti-La/SSB autoantibodies revolutionized diagnostic accuracy. Anti-Ro/SSA antibody was first described in 1969 by Aljarchevsky, and anti-La/SSB antibody was discovered in 1974 by Greenwood et al. These antibodies became essential tools in diagnosis and research as immunological markers of Sjögren syndrome.
Diagnosis was standardized with the publication of the American-European Consensus Group (AECG) classification criteria in 2002 and the joint ACR/EULAR classification criteria in 2016 (the current standard). In Korea, Sjögren syndrome was designated for the rare disease Special Copayment Reduction (V139) from the 2010s, strengthening the management system, and patient support is provided centered on the Korean College of Rheumatology and the Korean Sjögren Syndrome Patients' Association.
The cause of Sjögren syndrome is understood by a multifactorial etiology model in which genetic susceptibility, environmental triggers, and hormonal factors interact in a complex way to induce an autoimmune response targeting the exocrine glands (lacrimal glands, salivary glands, other exocrine glands).
Autoimmune abnormality: The core pathogenesis is loss of function of exocrine gland epithelial cells attacked by autoreactive T cells and B cells. CD4+ T helper cells, particularly Th17 cells and T follicular helper cells (Tfh), infiltrate the salivary and lacrimal glands, secrete IL-17 and IL-21, and promote B-cell activation and antibody production. As a result of B-cell hyperactivation, anti-Ro/SSA and anti-La/SSB autoantibodies are produced. Anti-Ro/SSA antibodies bind Ro52 (TRIM21)/Ro60 (TROVE2) antigens on the surface of gland epithelial cells, and anti-La/SSB antibodies bind La (SSB)/nucleic acid complexes, and may be involved in direct tissue damage, such as by promoting apoptosis.
Innate immunity and type I interferon: After pattern recognition by TLR (Toll-like receptor) 3, 7, and 9 in exocrine gland epithelial cells, an 'interferon signature', with increased expression of type I interferon (IFN-α/β) and interferon-stimulated genes (ISG), is clearly observed in the blood and salivary glands in Sjögren syndrome. Type I interferon amplifies activation of adaptive immunity through dendritic cells and monocytes and promotes excessive secretion of BAFF (B-cell activating factor), sustaining B-cell hyperactivation and autoantibody production.
Environmental triggers: There is a hypothesis that Epstein-Barr virus (EBV) infection can induce an autoimmune response against Ro/La antigens through molecular mimicry. Coronaviruses (including SARS-CoV-2), retroviruses, and human T-lymphotropic virus (HTLV-1) are also being studied for association with Sjögren syndrome. In particular, new-onset or worsened dryness symptoms and seroconversion to anti-Ro/SSA antibody after SARS-CoV-2 infection have been reported and are attracting attention.
Hormonal factors: The female predominance in Sjögren syndrome (about 9–15:1) suggests an immunoregulatory role of sex hormones, particularly estrogen. There is evidence that estrogen promotes B-cell activation and autoantibody production and directly affects the secretory function of the lacrimal and salivary glands. There are also epidemiological observations that postmenopausal estrogen decline is associated with worsening dry eye.
Sjögren syndrome is a polygenic complex-inheritance autoimmune disease in which HLA gene associations and several non-HLA susceptibility gene variants contribute to onset.
HLA association: The association with HLA-DR3 (DRB1*03:01) and HLA-DQ2 (DQB1*02:01) is the strongest, particularly prominent in patients of European ancestry. This HLA combination is especially strongly associated with positivity for anti-Ro/SSA and anti-La/SSB antibodies. HLA-DR2 (DRB1*15:01) and HLA-DQ6 are also reported as risk alleles in some populations. In patients of Asian ancestry (Korea, Japan, China), the HLA association pattern differs somewhat from that in the West, and there are studies showing that HLA-DRB1*08:03 shows a relatively stronger association in Asians. HLA genotype is partly associated with autoantibody profile, disease severity, and pattern of extraglandular involvement.
Non-HLA genetic associations: Several non-HLA susceptibility genes have been identified through GWAS. IRF5: amplifies type I interferon response; one of the strongest non-HLA risk genes in Sjögren syndrome. STAT4: IFN-γ and IL-12 signaling pathway, Th1/Th17 activation, particularly associated with anti-Ro/SSA-positive patients. BLK: regulation of B-cell receptor signaling, related to B-cell hyperactivation and autoantibody production. TNIP1 (TNFAIP3-interacting protein 1): regulation of NF-κB signaling inhibition; with variants, overactive NF-κB → amplified inflammation. CXCR5: chemokine receptor regulating migration of T follicular helper cells (Tfh), involved in ectopic lymphoid follicle formation. Ectopic lymphoid structures (ELS) form within the salivary glands and become the breeding ground for B-cell lymphoma. The association of ELS formation with CXCR5 and CXCL13 gene variants is being studied for predicting lymphoma risk.
Epigenetics: Abnormal DNA methylation of fibrosis and immune regulation genes is observed in salivary gland epithelial cells and peripheral blood B cells and T cells of patients with Sjögren syndrome. MicroRNAs such as miR-155, miR-21, and miR-146a are associated with immune dysregulation. In particular, there are studies showing that decreased miR-146a causes NF-κB overactivation and amplified type I interferon secretion through loss of suppression of IRAK1 and TRAF6.
Neonatal lupus and anti-Ro antibodies: In newborns born to mothers positive for anti-Ro/SSA antibodies, maternal anti-Ro/SSA antibodies cross the placenta and can cause neonatal lupus or congenital complete heart block (CHB). The incidence of CHB is about 2–3% in anti-Ro-positive pregnant women, and rises to about 15–20% recurrence if there is a history of delivering an affected child. This is the only clinical example of an autoantibody–tissue damage link in which autoantibodies directly injure the fetal cardiac conduction system tissue.
Sjögren syndrome is the second most common autoimmune rheumatic disease after rheumatoid arthritis, with an estimated 0.1–0.6% of the population affected worldwide. However, diagnostic delay is common (average diagnostic delay about 5–7 years) and many cases are asymptomatic or mild, so the actual prevalence is thought to be higher than official statistics.
Sex and age distribution: Female predominance is very marked, with a female:male ratio of about 9–15:1. Age of onset is concentrated in the 40s–60s, and the perimenopausal period is the most common time of onset. Onset in the 50s is most common, and onset before the 30s is relatively rare at about 10–15% of the total. Juvenile Sjögren syndrome is very rare.
Primary versus secondary Sjögren syndrome: Primary (primary Sjögren, pSS) occurs independently without other autoimmune disease and accounts for about 50% of the total. Secondary (secondary Sjögren, sSS) occurs together with other autoimmune diseases such as rheumatoid arthritis (about 30%), systemic lupus erythematosus (about 20%), systemic sclerosis (about 15%), and primary biliary cholangitis (about 5%). Secondary Sjögren is intricately intertwined with the course, treatment, and prognosis of the underlying autoimmune disease.
Epidemiology in Korea: According to Health Insurance Review & Assessment Service (HIRA) data, the number of patients treated for Sjögren syndrome was about 90,000–100,000 as of 2022. The number of patients registered for rare disease Special Copayment Reduction (V139) is lower than this, but considering that a considerable number of mild or secondary patients are unregistered, the actual number of treated patients is estimated to be higher. In domestic studies, the anti-Ro/SSA antibody positivity rate is about 60–70% and the anti-La/SSB antibody positivity rate about 30–40%, similar to the West. A domestic study reports that the risk of B-cell lymphoma is about 10–20 times higher than in the general population.
Lymphoma risk: Sjögren syndrome is one of the autoimmune diseases with the highest risk of B-cell lymphoma (especially mucosa-associated lymphoid tissue marginal zone B-cell lymphoma, MALToma). The risk of lymphoma is about 15–20 times that of the general population, and lymphoma develops over a lifetime in 5–10% of pSS patients. High-risk factors for lymphoma include parotid enlargement, positive serum cryoglobulin, low C4 complement, high serum immunoglobulins (especially IgG), ectopic lymphoid follicle formation, high-titer anti-Ro antibody, and a high lymphocytic infiltration score (focus score).
The pathophysiology of Sjögren syndrome consists of a self-amplifying immune circuit in which activation of exocrine gland epithelial cells, the type I interferon response, T-cell and B-cell infiltration, and autoantibody production cycle.
Epithelial cell activation and innate immunity: When salivary and lacrimal gland epithelial cells are activated by initial triggers such as viral infection (especially EBV, coronavirus), oxidative stress, and hormonal stimulation, innate immune signaling is initiated through TLR3, TLR7 (recognition of single-stranded RNA), and TLR9 (recognition of unmethylated CpG DNA). Activated epithelial cells secrete cytokines and chemokines such as BAFF (B-cell activating factor, BLyS), APRIL (a proliferation-inducing ligand), type I interferon, CXCL10, and CXCL13, recruiting T cells and B cells to the salivary glands.
T-cell infiltration and adaptive immunity: CD4+ T helper cells are the main cellular component of salivary gland infiltrates, and Th17 cells (secreting IL-17) and T follicular helper cells (Tfh, secreting IL-21) are particularly important. IL-17 directly stimulates epithelial cells and impairs gland function, and IL-21 strongly stimulates B-cell survival, proliferation, and antibody secretion. CD8+ cytotoxic T cells also infiltrate and damage gland epithelial cells through perforin-granzyme mechanisms. Decreased function of regulatory T cells (Treg) contributes to the breakdown of immune tolerance.
B-cell hyperactivation and autoantibodies: B cells hyperactivated by BAFF, APRIL, and IL-21 differentiate into plasma cells and secrete anti-Ro/SSA and anti-La/SSB autoantibodies. Anti-Ro/SSA antibodies bind Ro52 (TRIM21) and Ro60 proteins, and bind directly to Ro antigens exposed on the cell surface during apoptosis of gland epithelial cells, aggravating gland damage through complement activation, ADCC, and direct functional inhibition. Ectopic lymphoid follicles (germinal center-like structures) form within the salivary glands, where local B-cell affinity maturation and clonal expansion occur, and these become precursor lesions for the development of MALToma. Formation of cryoglobulins (immunoglobulin complexes that precipitate on cooling) causes vasculitis and renal failure.
Mechanism of decreased gland function: Antibodies against the M3 muscarinic receptor (M3R) are detected in some patients, and there is a hypothesis that these antibodies block secretory signals from autonomic stimulation and worsen dryness symptoms. A mechanism has also been proposed in which the neuroeffector junction between nerve endings and gland cells is physically blocked by inflammatory cell infiltration. Decreased expression and dysregulation of the water channel aquaporin (AQP5) are observed in the lacrimal and salivary glands, and redistribution of AQP5 (apical → intracellular) contributes to decreased secretory capacity.
The clinical symptoms of Sjögren syndrome are broadly divided into dryness symptoms due to exocrine gland involvement and extraglandular symptoms due to systemic involvement.
Dry eye (keratoconjunctivitis sicca): Dry eye, caused by decreased tear secretion and tear film instability, occurs in about 90% of patients. A foreign body sensation as if sand is in the eye, burning, itching, redness, and sensitivity to light (photophobia) are characteristic. Blinking often provides temporary relief. In severe cases it can progress to corneal epithelial damage, corneal ulcer, and reduced vision. If left untreated for a long time, there is a risk of corneal scarring and vision loss.
Dry mouth (xerostomia): Dry mouth, caused by decreased saliva secretion, occurs in about 90% of patients. Difficulty chewing and swallowing food (especially dry food), difficulty speaking, taste changes (hypogeusia, dysgeusia), and burning mouth occur. With reduced oral self-cleansing capacity, dental caries increase rapidly, with cervical and lingual-surface caries being characteristic. Oral candidiasis (thrush) commonly accompanies. The parotid and submandibular glands may swell intermittently or persistently (parotid enlargement).
Systemic symptoms: Extreme fatigue is the symptom that most reduces quality of life, and about 60–70% of patients complain of severe fatigue. Arthralgia and arthritis occur in about 50%, and are generally non-erosive and non-deforming. Myalgia is also common.
Extraglandular involvement: Peripheral nervous system involvement occurs in about 20–30%, presenting as sensory neuropathy (especially small fiber neuropathy and sensory ataxic neuropathy) and cranial nerve involvement (trigeminal neuralgia-like symptoms, facial nerve palsy). Lung involvement (ILD resembling that of SSc, airway dryness) occurs in about 10–15%. Renal involvement manifests as renal tubulo-interstitial disorder (renal tubular acidosis, with distal RTA type I being the most common), presenting with hypokalemia, muscle weakness, and nephrolithiasis. Vasculitis presents as purpura and lower limb ulcers in patients with cryoglobulinemia. Dry skin, vaginal dryness, and vulvar pain are also common mucosal symptoms.
The physical signs of Sjögren syndrome consist of objective indicators of dryness and signs of systemic involvement.
Ophthalmologic signs: Schirmer test: the standard test measuring tear secretion; tear secretion of 5 mm or less in 5 minutes is abnormal. Fluorescein sodium corneal staining and lissamine green conjunctival staining show corneal and conjunctival epithelial defects (pink or yellow staining), which are quantified by the Ocular Surface Staining Score (OSS) or the van Bijsterveld score. Tear film breakup time (TBUT) <10 seconds is an indicator of tear film instability.
Oral and salivary gland signs: On measurement of unstimulated salivary flow rate (UWS), <1.5 mL in 15 minutes (or <0.1 mL per minute) is abnormal. Findings include a dry oral mucosa to which a mirror or tongue depressor sticks easily, multiple cervical and lingual-surface caries, and oral candidiasis (white patches, erythema). Parotid enlargement is palpated as a painless bilateral or unilateral swelling and may contain calcified salivary stones.
Salivary gland biopsy (lip biopsy): Minor salivary glands beneath the mucosa of the inner lower lip (lip biopsy) are examined histologically to quantify lymphocytic infiltration foci. 1 focus is defined as an aggregate of ≥50 lymphocytes within 4 mm² of gland tissue, and a focus score ≥1/4 mm² is positive. The lip biopsy is the item given the highest weight (3 points) in the 2016 ACR/EULAR criteria.
Serological signs: Positive anti-Ro/SSA antibody (3 points in the 2016 ACR/EULAR criteria). Positive anti-La/SSB antibody (not included in the criteria alone). Positive ANA (about 80%), positive RF (about 60%), hypergammaglobulinemia, elevated serum β2-microglobulin, positive cryoglobulin (about 10–15%), and low C3/C4 complement are predictors of lymphoma risk. ESR and CRP are mildly elevated or normal.
Signs of extraglandular involvement: Renal tubular acidosis (distal RTA type I): hypokalemia, hyperchloremia, alkaline urine (urine pH >5.5). Peripheral neuropathy: decreased ankle reflexes, decreased vibration sense, altered pinprick pain sensation. Vasculitis: palpable purpura (both lower limbs), skin ulcers. Dry skin: dry, scaly skin.
The key to screening for early diagnosis of Sjögren syndrome is to combine autoantibody screening and functional tests in patients complaining of dryness symptoms. In addition, regular surveillance for early detection of complications such as lymphoma is important in confirmed patients.
Screening in patients with dryness symptoms: Perform autoantibody screening immediately in patients with concurrent dry eye and dry mouth, or with unexplained parotid enlargement, recurrent caries, or fatigue. Measure ANA (indirect immunofluorescence, IF, on HEp-2 cell substrate) together with anti-Ro/SSA and anti-La/SSB antibodies. The anti-Ro/SSA positivity rate is about 60–70%, and because diagnosis is possible with a positive lip biopsy even if negative, consider biopsy when clinical suspicion is strong even with negative anti-Ro. The Schirmer test (simple and cost-effective) can be performed in primary care before referral to ophthalmology.
Surveillance of patients at risk for lymphoma: In high-risk patients (parotid enlargement, positive cryoglobulin, low C4, high-titer anti-Ro/SSA, history of confirmed ELS), perform regular parotid ultrasound, serum IgG and monoclonal protein (serum protein electrophoresis), β2-microglobulin, and blood counts. A heterogeneous echo pattern, cystic lesions, and enlarged lymph nodes on parotid ultrasound may suggest precursor lesions of lymphoma. If findings suspicious for lymphoma are present, confirm with CT/PET-CT and biopsy.
Screening for extraglandular involvement: After confirmation, perform pulmonary function tests (FVC, DLCO), chest HRCT (screening for ILD), urinalysis (pH, proteinuria, evaluation for renal tubular acidosis), and nerve conduction studies (screening for peripheral neuropathy) as baselines, and repeat when symptoms change. In pregnant patients with Sjögren syndrome (anti-Ro/SSA positive), perform fetal ECG and echocardiographic monitoring at 16–24 weeks of gestation to screen fetal cardiac conduction function.
The diagnosis of Sjögren syndrome is based on the classification criteria published by ACR/EULAR in 2016, using a scoring system (met when the total is 4 points or more).
2016 ACR/EULAR classification criteria: ① Focus score ≥1/4 mm² on lip biopsy: 3 points ② Positive anti-Ro/SSA antibody: 3 points ③ Ocular Staining Score (OSS) ≥5 or van Bijsterveld score ≥4: 1 point ④ Schirmer test ≤5 mm/5 min: 1 point ⑤ Unstimulated salivary flow (UWS) ≤1.5 mL/15 min: 1 point. The classification criteria are met if the total is 4 points or more. The sensitivity of these criteria is 97% and specificity 90%. Exclusion criteria: history of head and neck radiotherapy, active HCV infection, AIDS, sarcoidosis, amyloidosis, graft-versus-host disease, and IgG4-related disease must be excluded.
Differential diagnosis: IgG4-related disease (IgG4-RD) causes salivary and lacrimal gland enlargement, orbital swelling, and multi-organ fibrosis, resembling Sjögren syndrome. Elevated serum IgG4 and histological IgG4+ plasma cell infiltration and fibrosis (storiform fibrosis) are the differentiating indicators. Differentiation is also needed from sarcoidosis, lymphoma, and drug-induced dryness (anticholinergics, antidepressants, diuretics). Secondary Sjögren syndrome accompanying other autoimmune diseases (lupus, rheumatoid arthritis, systemic sclerosis) is differentiated by the clinical and serological characteristics of the underlying disease.
ESSDAI and ESSPRI: ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index, assessing 12 domains of extraglandular involvement) is the standard for assessing Sjögren syndrome disease activity, and ESSPRI (EULAR Sjögren's Syndrome Patient Reported Index: 3 items of dryness, fatigue, and pain, each scored 0–10) is used to assess patient symptom burden. ESSDAI is divided into low (<5 points), moderate (5–13 points), and high (≥14 points) and used to determine treatment intensity.
Treatment of Sjögren syndrome consists of two axes: relief of dryness symptoms and control of systemic involvement. There is currently no curative treatment, and the goals are symptom control, improved quality of life, and prevention of complications.
Treatment of dry eye: Artificial tears are first-line treatment, with hyaluronic acid-based, carboxymethylcellulose (CMC), and polyvinyl alcohol preparations used. Preservative-free single-dose artificial tears are safer for long-term use. 1% cyclosporine eye drops (Restasis) are an immunomodulatory treatment that suppresses inflammation and improves tear secretion. Lifitegrast eye drops (an integrin antagonist) can also be used to treat dry eye. In severe keratoconjunctivitis sicca, tear drainage is blocked with punctal plugs, and education on avoiding low-humidity environments and blinking frequently during screen use is important. Apply artificial tears frequently during the day, and use a gel or artificial tear ointment before bedtime.
Treatment of dry mouth: Salivary stimulation is induced by drinking water frequently, chewing sugar-free gum, and using saliva-stimulating candies. Sugar-free artificial saliva (carboxymethylcellulose-based) is available. Pilocarpine (an M3 muscarinic receptor agonist, 5 mg 3–4 times a day) increases saliva secretion when residual salivary gland function is present. Cevimeline (30 mg 3 times a day) is a salivary secretion stimulant with a similar mechanism. For oral candidiasis, topical antifungals (nystatin, clotrimazole troches) are used. Dental care: fluoride varnish application, use of xylitol-containing products, regular scaling, and early treatment of caries.
Systemic therapy: Hydroxychloroquine (HCQ, 200–400 mg/day) is recommended first-line for improving systemic symptoms of Sjögren syndrome (fatigue, arthralgia, myalgia) and serum immune markers. Evidence from prospective clinical trials is limited, but it has a favorable safety profile and can be given long term. There are no drugs specific to fatigue, and regular aerobic exercise, sleep hygiene, and cognitive behavioral therapy (CBT) are helpful. If arthritis persists, NSAIDs, HCQ, low-dose steroids, and MTX are used in stepwise fashion.
Treatment of extraglandular involvement: Glomerulonephritis and severe renal tubular acidosis: steroids, cyclophosphamide if necessary. Hypokalemia of renal tubular acidosis: potassium citrate supplementation. ILD: MMF, steroids, nintedanib. Peripheral neuropathy: HCQ, IVIG, steroids. Vasculitis (cryoglobulinemia): steroids, rituximab, plasma exchange. Rituximab (RTX, an anti-CD20 monoclonal antibody) is effective in severe extraglandular involvement (vasculitis, neuropathy, severe cytopenia, pre-lymphoma stage) and is an evidence-based choice grounded in the pathogenesis of Sjögren syndrome, in which B-cell hyperactivation is central.
The prognosis of Sjögren syndrome differs greatly depending on the pattern of systemic involvement and whether lymphoma develops. Patients with dryness symptoms alone have almost normal life expectancy, but when severe extraglandular involvement or lymphoma occurs, morbidity and mortality increase substantially.
Survival and causes of death: A large cohort study found that the overall life expectancy of patients with primary Sjögren syndrome is not significantly lower than that of the general population, but the risk of death increases in patients with lymphoma, severe renal involvement, or lung involvement. B-cell lymphoma (especially MALT lymphoma) is a major cause of death in patients with Sjögren syndrome, and the prognosis worsens sharply upon transformation to high-grade lymphoma. Cryoglobulinemic vasculitis raises the risk of renal failure, stroke, and severe infection.
Quality of life: Extreme fatigue, chronic pain, dryness symptoms, depression, and anxiety greatly reduce the quality of life of patients with Sjögren syndrome. An ESSPRI score ≥5 indicates high symptom burden, and one study found that about 60–70% of patients meet this criterion. Limitations on work activity and reduced social functioning are also common. Long-term complications such as caries and visual loss place additional burden on quality of life.
Lymphoma risk prediction: ESSDAI score, parotid enlargement, positive cryoglobulin, low C4, high-titer anti-Ro, and the presence of ectopic lymphoid follicles (ELS) are used for lymphoma risk stratification. Lymphoma prediction tools such as the PRAISE (Predicting Risk and Outcome in Sjögren's Syndrome) score published in 2024 have begun to be used in clinical practice. In high-risk patients, early detection is pursued with regular parotid ultrasound, serum monoclonal protein, and blood counts.
Follow-up: Disease activity indicators such as ESSDAI and the patient-reported indicator ESSPRI are evaluated regularly. Depending on the presence of extraglandular involvement (lung, kidney, nerve), consult the relevant specialty, and in pregnant patients with Sjögren syndrome, strengthen monitoring of fetal cardiac conduction. Patients registered for Special Copayment Reduction (V139) in Korea receive medical expense relief benefits, and regular follow-up according to Korean College of Rheumatology guidelines is recommended.
There is no established method to prevent the onset of Sjögren syndrome itself, and early detection and prevention of complications are the main prevention strategies.
Primary prevention (reducing the risk of onset): There is as yet no established method to directly prevent the onset of Sjögren syndrome. General hygiene management and vaccination to prevent infection with trigger viruses (EBV, etc.) may help indirectly. Smoking worsens decreased salivary gland function and dry mouth, so smoking cessation is recommended. Alcohol intake and excessive caffeine intake worsen dry mouth and dry eye, so they should be limited.
Secondary prevention (early detection): When dry eye and dry mouth appear together, or when there is idiopathic parotid enlargement, recurrent caries, or unexplained extreme fatigue, perform autoantibody (ANA, anti-Ro/SSA) screening and ophthalmologic evaluation (Schirmer test) immediately. Observational studies suggest that starting baseline treatment such as HCQ after early diagnosis helps prevent extraglandular involvement and reduce lymphoma risk. Anti-Ro/SSA-positive women are educated through genetic counseling before pregnancy about the risk of neonatal lupus and congenital complete heart block.
Tertiary prevention (suppressing progression of complications): Dry eye: prevent corneal damage with regular use of artificial tears, regular ophthalmologic checkups (every 6–12 months), avoiding or minimizing contact lens use, and avoiding dry environments (direct air from air conditioners and heaters). Dry mouth: prevent caries and oral candidiasis with dental checkups every 6 months, fluoride application, use of xylitol gum and candies, and alcohol-free mouthwash. In patients at high risk for lymphoma, early detection of lymphoma is pursued with regular parotid ultrasound and surveillance of serum monoclonal protein. In patients with extraglandular involvement receiving immunosuppressive therapy, perform appropriate infection prevention (pneumococcal and influenza vaccination, PCP prophylaxis).
Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. Arthritis Rheumatol. 2017;69(1):35-45. DOI: 10.1002/art.39859. PMID: 27785888.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome. Ann Rheum Dis. 2020;79(1):3-18. DOI: 10.1136/annrheumdis-2019-216114. PMID: 31806636.
Nocturne G, Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nat Rev Rheumatol. 2018;14(3):133-145. DOI: 10.1038/nrrheum.2018.1. PMID: 29362475.
Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. DOI: 10.1038/nrdp.2016.47. PMID: 27383715.
Risselada AP, Kruize AA, Goldschmeding R, et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. Ann Rheum Dis. 2010;69(7):1363-1367. DOI: 10.1136/ard.2009.115303. PMID: 19910295.
Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol. 2010;6(9):529-537. DOI: 10.1038/nrrheum.2010.118. PMID: 20703226.
Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI): a user guide. RMD Open. 2015;1(1):e000014. DOI: 10.1136/rmdopen-2014-000014. PMID: 26509055.
Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjögren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796-803. DOI: 10.1136/ard.2005.041186. PMID: 16284099.
Colafrancesco S, Ciccacci C, Priori R, et al. STAT4, TRAF3IP2, IL10, and HCP5 polymorphisms in Sjögren's syndrome: association with disease activity and clinical manifestations. J Immunol Res. 2019;2019:7682827. DOI: 10.1155/2019/7682827. PMID: 31781661.
Kim JW, Kim SM, Kwok SK, et al. Epidemiology and clinical characteristics of Sjögren's syndrome in Korea: a nationwide cross-sectional study using health insurance claims data. Korean J Intern Med. 2021;36(5):1237-1246. DOI: 10.3904/kjim.2020.268. PMID: 33186471.